-

Gamida Cell to Present at 2020 Virtual Cell & Gene Meeting on the Mesa

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to finding cures for blood cancers and serious blood diseases, today announced that Michele Korfin, chief operating and chief commercial officer, will present at the annual Cell & Gene Meeting on the Mesa to be held virtually next week.

The following are specific details regarding Gamida Cell’s presentation at the conference:

  • Event: 2020 Virtual Cell & Gene Meeting on the Mesa
  • Date: Monday, October 12 – Friday, October 16
  • Time: Company presentations will be available to view on-demand throughout the entirety of the conference

Please visit www.meetingonthemesa.com for full information including registration. Complimentary attendance at this event is available for credentialed investors and members of the media only. Investors should contact Laura Stringham at lstringham@alliancerm.org and interested media should contact Kaitlyn Dupont at kdupont@alliancerm.org.

About Gamida Cell

Gamida Cell is an advanced cell therapy company committed to finding cures for blood cancers and serious blood diseases. We harness our cell expansion platform to create therapies with the potential to redefine standards of care in areas of serious medical need. For additional information, please visit www.gamida-cell.com or follow Gamida Cell on LinkedIn or Twitter at @GamidaCellTx.

Contacts

Jaren Irene Madden
jaren@gamida-cell.com
1-617-286-6264

Matthew Corcoran (media)
mcorcoran@tenbridgecommunications.com
1-617-866-7350

Gamida Cell Ltd.

NASDAQ:GMDA

Release Summary
Gamida Cell will present at the annual Cell & Gene Meeting on the Mesa to be held virtually October 12 - 16, 2020.
Release Versions
$Cashtags

Contacts

Jaren Irene Madden
jaren@gamida-cell.com
1-617-286-6264

Matthew Corcoran (media)
mcorcoran@tenbridgecommunications.com
1-617-866-7350

Social Media Profiles
More News From Gamida Cell Ltd.

Gamida Cell Announces Closing of $25 Million Financing With Highbridge

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), the global leader in the development of NAM-enabled cell therapies for patients with hematologic and solid cancers and other serious diseases, announced the closing of a senior secured convertible term loan of $25 million with certain funds managed by Highbridge Capital Management, LLC (collectively, “Highbridge”). Pursuant to the loan agreement, Gamida Cell’s wholly-owned subsidiary, as borrower, will draw down $25 million from the faci...

Gamida Cell to Present Corporate Highlights at Multiple Upcoming Investor Conferences

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapies for patients with hematologic and solid cancers and other serious diseases, today announced that members of the management team will present at the following upcoming investor conferences: 34th Annual Piper Sandler Healthcare Conference, November 29, 2022 with a fireside chat at 1:00 p.m. ET. Evercore ISI Healthcare Conference, December 1, 2022 with a fireside chat at 2:15 p.m....

Gamida Cell Provides Regulatory Update on Omidubicel

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapies for patients with hematological and solid cancers and other serious diseases, today provided an update on recent interactions with the U.S. Food and Drug Administration (FDA) relating to the company’s Biologics License Application (BLA) for omidubicel, the company’s advanced cell therapy candidate for allogeneic hematopoietic stem cell transplant. As part of its ongoing BLA revi...
Back to Newsroom